Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare cancers research: Current state of knowledge and emerging opportunities for prevention and interception.

Journal of the National Cancer Institute·2026
Same author

Yes, It Is Worth It: Consider Participant Experiences in the Design of Future Trials.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease.

iScience·2026
Same author

Editor's Note: Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway.

Cancer research·2025
Same author

RSK1 and RSK2 as therapeutic targets: an up-to-date snapshot of emerging data.

Expert opinion on therapeutic targets·2024
Same author

Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.

Vaccine·2024

Related Experiment Video

Updated: Jun 1, 2026

Sample Preparation for Mass Spectrometry-based Identification of RNA-binding Regions
10:52

Sample Preparation for Mass Spectrometry-based Identification of RNA-binding Regions

Published on: September 28, 2017

RSK2 Binding Models Delineate Key Features for Activity.

Rick Gussio1, Michael J Currens, Dominic A Scudiero

  • 1Information Technology Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick, Maryland 21702 (USA).

Journal of Chemical and Pharmaceutical Research
|October 1, 2011
PubMed
Summary
This summary is machine-generated.

p90 ribosomal s6 kinase 2 (RSK2) is a cancer target. New binding models reveal key interaction sites, Val131 and Leu147, for developing potent RSK2 inhibitors and advancing cancer therapeutics.

More Related Videos

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)
07:22

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

Published on: January 12, 2024

Related Experiment Videos

Last Updated: Jun 1, 2026

Sample Preparation for Mass Spectrometry-based Identification of RNA-binding Regions
10:52

Sample Preparation for Mass Spectrometry-based Identification of RNA-binding Regions

Published on: September 28, 2017

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)
07:22

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

Published on: January 12, 2024

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • p90 ribosomal s6 kinase 2 (RSK2) is overexpressed and activated in human cancers, making it a promising therapeutic target.
  • Existing RSK2 inhibitors lack comprehensive structural information for rational drug design, with only one crystal structure available in complex with an AMP analogue.

Purpose of the Study:

  • To determine the RSK2 activity of structurally diverse compounds using a fluorescence polarization assay.
  • To model the binding modes of these compounds within an energy-refined crystal structure of RSK2.
  • To identify key interaction sites crucial for potent RSK2 inhibition.

Main Methods:

  • Utilized a fluorescence polarization assay to quantify RSK2 activity for various compounds.
  • Employed all-atom, energy-refined molecular modeling to simulate compound binding to RSK2.
  • Analyzed binding models to pinpoint critical amino acid residues involved in inhibition.

Main Results:

  • Identified Val131 and Leu147 as key amino acid residues mediating potent RSK2 inhibition.
  • Developed structure-based binding models providing insights into RSK2-inhibitor interactions.
  • Established a pharmacophore model for RSK2 inhibition based on structural data.

Conclusions:

  • The identified key interaction sites (Val131, Leu147) are crucial for potent RSK2 inhibition.
  • The developed structure-based pharmacophore serves as a valuable tool for discovering and refining novel RSK2 inhibitors.
  • This research facilitates the development of targeted cancer therapeutics by providing a structural basis for RSK2 inhibition.